Foresee Pharmaceuticals reports positive Phase 1 trial results for Linvemastat

Foresee Pharmaceuticals (TPEx: 6576) has reported successful preliminary results from its Phase 1 clinical trial of linvemastat (FP-020), an innovative and selective matrix metalloproteinase-12 (MMP-12) ... Read More